| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.56▲ | 0.57▲ | 0.57▲ | 0.57▼ | 0.66▼ |
| MA10 | 0.56▲ | 0.57▼ | 0.58▼ | 0.62▼ | 0.66▼ |
| MA20 | 0.58▼ | 0.59▼ | 0.62▼ | 0.68▼ | 0.68▼ |
| MA50 | 0.62▼ | 0.64▼ | 0.66▼ | 0.68▼ | 0.84▼ |
| MA100 | 0.67▼ | 0.70▼ | 0.69▼ | 0.69▼ | 0.93▼ |
| MA200 | 0.68▼ | 0.69▼ | 0.68▼ | 0.83▼ | 1.49▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.001▲ | -0.002▼ | -0.017▼ | 0.000▼ |
| RSI | 44.421▼ | 40.517▼ | 38.913▼ | 31.509▼ | 37.136▼ |
| STOCH | 43.996 | 36.946 | 32.522 | 32.550 | 47.702 |
| WILL %R | -53.030 | -53.030 | -56.338 | -80.821▼ | -86.070▼ |
| CCI | -5.975 | -27.859 | -47.607 | -107.185▼ | -198.060▼ |
|
Friday, March 27, 2026 05:04 AM
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript March 25, 2026 Cytosorbents Corporation misses on earnings expectations. Reported EPS is $-0.09 EPS, expectations were $-0.05.
|
|
Thursday, March 26, 2026 08:25 AM
Despite a modest revenue increase and strong international sales, CytoSorbents Corp (CTSO) faces hurdles in Germany and FDA resubmission efforts.
|
|
Wednesday, March 25, 2026 03:46 PM
Q4 2025 earnings call recap: record sales, Germany turnaround, DrugSorb-ATR FDA progress, and breakeven target.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/04/26 | 0.60 | 0.60 | 0.54 | 0.5473 | 76,253 |
| 31/03/26 | 0.58 | 0.60 | 0.532 | 0.5663 | 108,752 |
| 30/03/26 | 0.59 | 0.5999 | 0.5263 | 0.5599 | 246,485 |
| 27/03/26 | 0.62 | 0.62 | 0.5501 | 0.593 | 158,435 |
| 26/03/26 | 0.6112 | 0.6446 | 0.4992 | 0.6001 | 174,448 |
| 25/03/26 | 0.66 | 0.6955 | 0.6115 | 0.6713 | 70,741 |
| 24/03/26 | 0.695 | 0.75 | 0.66 | 0.6958 | 66,302 |
| 23/03/26 | 0.686 | 0.69 | 0.6628 | 0.6736 | 88,506 |
| 20/03/26 | 0.62 | 0.666 | 0.606 | 0.66 | 224,167 |
| 19/03/26 | 0.66 | 0.6997 | 0.60 | 0.638 | 196,785 |
|
|
||||
|
|
||||
|
|